Body System – Page 2

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

10 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

FDA’s Peter Marks Advocates for Open Dialogue on Vaccines Amid Controversy

10 months ago talkbio0Tagged BLOOD GROUP, JUNIOR SYSTEM, CHARGE Syndrome, nomination, Peter Marks, RFK gene, RFK Jr., United States Food and Drug Administration, Vaccines

FDA, Peter Marks, Vaccines, Open Dialogue, RFK Jr, HHS Nomination

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

10 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

10 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

10 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.

Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance

12 months ago talkbio0Tagged AlphaMedix, Cancer Therapeutic Procedure, Drug Industry, Neoplasms, Neurosecretory Systems, Novartis, radioligand therapy, Radiopharmaceuticals, sanofi

Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry

Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement

12 months ago talkbio0Tagged AlphaMedix, Multiple Epiphyseal Dysplasia, Neoplasms, Neurosecretory Systems, RadioMedix, Radiopharmaceuticals, sanofi

Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors

Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment

1 year ago talkbio0Tagged Cardiovascular system, China, etripamil nasal spray, Milestone, Paroxysmal, Paroxysmal supraventricular tachycardia, Pharmaceuticals Ltd, Regulatory Filing, Tenascin, human

Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies